Age May Influence the Impact of TRAbs on Thyroid Function and Relapse-Risk in Patients With Graves Disease.

CONTEXT Thyrotropin receptor antibodies (TRAbs) play a crucial role in the pathogenesis of Graves disease (GD). However, factors that influence the association of TRAbs with thyroid hormones and relapse risk in GD remain unclear. OBJECTIVE We investigated the associations of TRAbs at diagnosis with thyroid hormones and relapse risk and potential factors that can influence these associations in GD. DESIGN AND SETTING A prospective study in an endocrine center in England. PATIENTS AND MAIN OUTCOME MEASURES Three hundred eighty-four consecutive patients with GD who had measurements of TRAbs and thyroid hormones at diagnosis. The association of TRAbs with thyroid hormones and relapse risk was assessed through linear regression and Cox proportional hazard models, adjusted for confounders. RESULTS TRAbs were nonlinearly associated with thyroid hormones, following a curve with an initial positive slope and a subsequent flattening (P < 0.0001). Higher TRAbs were associated with greater relapse risk [hazard ratio (HR), 1.05 (95% CI, 1.02 to 1.08) per 1-U/L increase]. These associations were modified by age, but not by sex, race, smoking, or thyroid peroxidase antibody levels. In younger participants, increasing TRAbs were associated with higher thyroid hormones and greater relapse risk [HR, 1.13 (95% CI, 1.04 to 1.23) per 1-U/L increase]. In older participants, TRAbs were not associated with thyroid hormones or relapse risk [HR, 0.99 (95% CI, 0.93 to 1.05) per 1-U/L increase. CONCLUSIONS In GD, age can influence the effect of TRAbs on thyroid function and relapse risk. TRAbs at diagnosis have better predictive value in younger patients with GD.

[1]  A. Belfiore,et al.  Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism , 2020, Frontiers in Endocrinology.

[2]  P. Schuetz,et al.  Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. , 2017, European journal of endocrinology.

[3]  J. Seckl,et al.  Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse. , 2016, Thyroid : official journal of the American Thyroid Association.

[4]  A. Zwinderman,et al.  Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism. , 2016, The Journal of clinical endocrinology and metabolism.

[5]  H. Pijl,et al.  Human longevity is characterised by high thyroid stimulating hormone secretion without altered energy metabolism , 2015, Scientific Reports.

[6]  C. Marcocci,et al.  Diagnosis and classification of Graves' disease. , 2014, Autoimmunity reviews.

[7]  G. Barbesino,et al.  Clinical Utility of TSH Receptor Antibodies , 2013 .

[8]  D. Cooper,et al.  The incidence and prevalence of thyroid autoimmunity , 2012, Endocrine.

[9]  J. Beilby,et al.  Age-related changes in thyroid function: a longitudinal study of a community-based cohort. , 2012, The Journal of clinical endocrinology and metabolism.

[10]  F. Karlsson,et al.  Incidence of hyperthyroidism in Sweden. , 2011, European journal of endocrinology.

[11]  Victor M Montori,et al.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. , 2011, Thyroid : official journal of the American Thyroid Association.

[12]  B. Nedeljkovic-Beleslin Clinical assessment of patients with Graves' orbitopathy , 2011 .

[13]  J. Garber,et al.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. , 2011, Thyroid : official journal of the American Thyroid Association.

[14]  K. Zöphel,et al.  Clinical review about TRAb assay's history. , 2010, Autoimmunity reviews.

[15]  W. Wiersinga,et al.  Frequency and characteristics of TBII‐seronegative patients in a population with untreated Graves’ hyperthyroidism: a prospective study , 2008, Clinical endocrinology.

[16]  M. Castellano,et al.  Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. , 2007, Endocrine journal.

[17]  L. Wartofsky,et al.  Graves' disease. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  M. Nardi,et al.  Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. , 2006, European journal of endocrinology.

[19]  E. Kulinskaya,et al.  Does smoking increase relapse rates in Graves’ disease? , 2002, Journal of endocrinological investigation.

[20]  J. Franklyn,et al.  Age and gender predict the outcome of treatment for Graves' hyperthyroidism. , 2000, The Journal of clinical endocrinology and metabolism.

[21]  K. Usadel,et al.  Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. , 1999, The Journal of clinical endocrinology and metabolism.

[22]  A. Pinchera,et al.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. , 1997, Thyroid : official journal of the American Thyroid Association.

[23]  C. Franceschi,et al.  The aging thyroid. , 1995, Endocrine reviews.

[24]  K. Hashizume,et al.  Age‐Related Changes of Thyroid Function and Immunologic Abnormalities in Patients with Hyperthyroidism Due to Graves' Disease , 1989, Journal of the American Geriatrics Society.

[25]  F I Gilbert,et al.  Graves' Disease: Influence of Age on Clinical Findings , 1988 .